Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA) | Trials | Full Text

Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA) | Trials | Full Text

Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA)

Rheumatoid arthritis (RA) is one of the leading chronic inflammatory rheumatism. First-line therapy with synthetic disease-modifying antirheumatic drugs (sDMARD) is insufficiently effective in 40% of cases and...

Authors:Dalifer Freites-Núñez, Athan Baillet, Luis Rodriguez-Rodriguez, Minh Vu Chuong Nguyen, Isidoro Gonzalez, Jose Luis Pablos, Alejandro Balsa, Monica Vazquez, Philippe Gaudin and Benjamín Fernandez-Gutierrez

Citation:Trials 2020 21:755

Content type:Study protocol

 

Published on: 31 August 2020

• ViewFull Text
 
• ViewPDF